Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Genzyme

http://www.genzyme.com

Latest From Sanofi Genzyme

Flight Of The Navigator: Bluebird bio's Andrew Obenshain

For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.

Outlook 2023 C-Suite Speaks

New IO Progress For Korea's NeoImmuneTech, GI Innovation

While Chinese bioventures continue to surge ahead in immuno-oncology R&D, NeoImmuneTech says its long-acting human IL-7 in combination with pembrolizumab shows Phase IIa clinical efficacy in gastrointestinal tumors. Another Korean firm, GI Innovation, says its bispecific fusion protein/pembrolizumab combo shows synergistic effects in solid tumors at Phase I/II.

Clinical Trials ImmunoOncology

Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone

Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates. 

Financing Business Strategies

Commercializing Rare Disease Therapies Is Getting Tougher

For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.

Rare Diseases Pricing Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AnorMED
    • Bioenvision
    • ILEX Oncology, Inc.
    • Sangstat Medical Corporation
    • Genzyme Corporation
UsernamePublicRestriction

Register